2023 Archives - Biocryst

Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults

View Article

biocryst

February 5, 2026

Hereditary Angioedema (HAE)
STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema

View Article

biocryst

February 5, 2026

Hereditary Angioedema (HAE)
Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
The Multifactorial Impact of Receiving a Hereditary Angioedema Diagnosis

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Managing Diagnosis, Treatment and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Significant response to berotralstat in 3 patients with hereditary angioedema of unknown origin

View Article

biocryst

January 27, 2025

Hereditary Angioedema (HAE)
A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data

View Article

biocryst

January 27, 2025

Hereditary Angioedema (HAE)
Consequences of Insurance Coverage Delays and Denials for Patients With Hereditary Angioedema

View Article

biocryst

January 27, 2025

Hereditary Angioedema (HAE)
Prevalence of and risk factors for nutritional deficiency and food allergy in a cohort of 21 patients with Netherton syndrome

View Article

biocryst

January 27, 2025

Netherton Syndrome (NS)